en · de · es · fr · pt
aod-9604-notes.peptides6155.com › Faq › Regulatory And Analytical Context — Evidence Review

Regulatory And Analytical Context — Evidence Review

By Editorial Desk · published 2025-10-04 · last reviewed 2025-10-30 · Faq

The short version of regulatory status fits in a sentence. The long version — which is the one that helps — is below.

Reviewed 2025-10-30. Anything still debated is marked as such rather than presented as settled.

Regulatory and Analytical Context

Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.

In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.

Handling And Analytical Properties

AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.

Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.

Aod-9604 at a glance

PropertyValueNotes
Regulatory statusNot approved as a medicineStatus varies by country; prohibited in sport.
Common storage temperature2–8 °C for lyophilized powderProtect from light and moisture; follow supplier instructions.
Typical analytical methodLC-MS/MSUsed for identification and quantification in biological samples.
Purity assessmentHPLC and mass spectrometryReverse-phase HPLC is common for peptide purity.
Common synonymsAOD9604; hGH 176-191 fragmentNaming conventions differ across studies.

Identity and Research Origin

Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.

Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.

AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.

Related pages on this site

Mechanism and Regulatory Status

Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.

Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.

Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.

Background and Development History

Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.

Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.

AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.

Background from the literature

Emissions from vehicles such as cars and trucks can be a substantial outdoor source of PAHs in particulate air pollution. Geographically, major roadways are thus sources of PAHs, which may distribute in the atmosphere or deposit nearby. Catalytic converters are estimated to reduce PAH emissions from gasoline-fired vehicles by 25-fold. People can also be occupationally exposed from using fossil fuels or their derivatives, wood-burning, carbon electrodes, or exposure to diesel exhaust. Industrial activity that can produce and distribute PAHs includes aluminum, iron, and steel manufacturing; coal gasification, tar distillation, shale oil extraction; production of coke, creosote, carbon black, and calcium carbide; road paving and asphalt manufacturing; rubber tire production; manufacturing or use of metal working fluids; and activity of coal or natural gas power stations. In industrial countries, people who smoke tobacco products, or who are exposed to second-hand smoke, are among the most highly exposed groups; tobacco smoke contributes to 90% of indoor PAH levels in the homes of smokers. For the general population in developed countries, the diet is otherwise the dominant source of PAH exposure, particularly from smoking or grilling meat or consuming PAHs deposited on plant foods, especially broad-leafed vegetables, during growth. Exposure also occurs through drinking alcohol aged in charred barrels, flavored with peat smoke, or made with roasted grains. PAHs are typically at low concentrations in drinking water.

==== May ==== Clashes erupted between Sweida factions, and armed groups gathered around the village of Kanaker, west of Sweida. This coincided with clashes in the towns of Ira, Rasas and al-Soura al-Kabira. The shrine and museum of Issam Zahreddine, a late Druze military officer and former commander of the Syrian Republican Guard, was vandalized and burned in al-Soura al-Kabira. General security vehicles were ambushed on 7 May by what state media called "outlaw groups" affiliated with the Suwayda Military Council. Druze leader Hikmat al-Hijri declared that "There is no consensus between us and the Damascus government". That same day, videos were released showing Burkan al-Furat, a group from Deir ez-Zor, bombing the city of Suwayda and the "al-Hijri militias" from Daraa Governorate. According to activist Samer Salloum, it was the Syrian transitional government that allowed entry into the south. On 21 May 2025, an armed group, "led by Fadi Nasr, with support from Tariq al-Nagoush", took Mustafa al-Bakour, the governor of Suwayda governorate, hostage at the town hall, demanding and securing the release of Raghib Qarqout, who is a convicted car thief. The Men of Dignity movement was mobilised and secured the governor's exit route from the building, while the Al-Jabal Brigade engaged with the gunmen. Al-Bakour submitted his resignation two days later. On 22 May, the Islamic State claimed attacks in Al-Safa, in Suwayda Governorate, against the Ministry of Defense, being the first attack by the Islamic State against the Syrian transitional government, since the Fall of Assad.

Maggots in a single day would clean a wound much better than any agents we had at our command ... I am sure I saved many lives by their use. He recorded a high survival rate in patients he treated with maggots. During World War I, orthopedic surgeon William S. Baer recorded the case of a soldier left for several days on the battlefield who had sustained compound fractures of the femur and large flesh wounds. The soldier arrived at the hospital with maggots infesting his wounds but had no fever or other signs of infection and survived his injuries, which would normally have been fatal. After the war, Baer began using maggot therapy at Boston Children's Hospital in Massachusetts. There were reports that American prisoners of war of the Japanese in World War II resorted to maggot therapy to treat severe wounds. A survey of US Army doctors published in 2013 found that 10% of them had used maggot therapy.

Sources: en.wikipedia.org

Further detail

=== Angiogenesis as a therapeutic target === Angiogenesis may be a target for combating diseases such as heart disease characterized by either poor vascularisation or abnormal vasculature. Application of specific compounds that may inhibit or induce the creation of new blood vessels in the body may help combat such diseases. The presence of blood vessels where there should be none may affect the mechanical properties of a tissue, increasing the likelihood of failure. The absence of blood vessels in a repairing or otherwise metabolically active tissue may inhibit repair or other essential functions. Several diseases, such as ischemic chronic wounds, are the result of failure or insufficient blood vessel formation and may be treated by a local expansion of blood vessels, thus bringing new nutrients to the site, facilitating repair. Other diseases, such as age-related macular degeneration, may be created by a local expansion of blood vessels, interfering with normal physiological processes. The modern clinical application of the principle of angiogenesis can be divided into two main areas: anti-angiogenic therapies, which angiogenic research began with, and pro-angiogenic therapies. Whereas anti-angiogenic therapies are being employed to fight cancer and malignancies, which require an abundance of oxygen and nutrients to proliferate, pro-angiogenic therapies are being explored as options to treat cardiovascular diseases, the number one cause of death in the Western world.

Glyceraldehyde-3-phosphate can double up to form larger sugar molecules like glucose and fructose. These molecules are processed, and from them, the still larger sucrose, a disaccharide commonly known as table sugar, is made, though this process takes place outside of the chloroplast, in the cytoplasm. Alternatively, glucose monomers in the chloroplast can be linked together to make starch, which accumulates into the starch grains found in the chloroplast. Under conditions such as high atmospheric CO2 concentrations, these starch grains may grow very large, distorting the grana and thylakoids. The starch granules displace the thylakoids, but leave them intact. Waterlogged roots can also cause starch buildup in the chloroplasts, possibly due to less sucrose being exported out of the chloroplast (or more accurately, the plant cell). This depletes a plant's free phosphate supply, which indirectly stimulates chloroplast starch synthesis. While linked to low photosynthesis rates, the starch grains themselves may not necessarily interfere significantly with the efficiency of photosynthesis, and might simply be a side effect of another photosynthesis-depressing factor.

=== Automation === The technology has been automated, leading to a dramatic increase in the efficiency of amplification. Now, a single cycle results in a 2500-fold increase in sensitivity of detection over western blotting, whereas 2 and 7 consecutive cycles result in 6 million and 3 billion-fold increases in sensitivity of detection over western blotting, a technique widely used in BSE surveillance in several countries.

== Awards and recognitions == Rex has been named one of the top 100 hospitals in the country by Thomson (2008) and named one of the Best Places to Work in Healthcare by Modern Healthcare (2008). In 2014, Rex was recognized as the hospital with the best patient interactions in the state of North Carolina. In a study done by an independent company, Axial Exchange, Rex was ranked highest based on readmissions, patient satisfaction, and self care tools and education. In 2010, it was named a Bariatric Center of Excellence by the American Society for Bariatric Surgery. Rex was the first hospital in the Triangle, and one of only 10 in North Carolina to receive Magnet Recognition, which places Rex nurses among the top two percent in the country.

Sources: en.wikipedia.org

Background from the literature

Irresponsibility on the part of the radioactive material's owners, usually a hospital, university, or military, and the absence of regulation concerning radioactive waste, or a lack of enforcement of such regulations, have been significant factors in radiation exposures. For an example of an accident involving radioactive scrap originating from a hospital, see the Goiânia accident. Transportation accidents involving spent nuclear fuel from power plants are unlikely to have serious consequences due to the strength of the spent nuclear fuel shipping casks. On 15 December 2011, top government spokesman Osamu Fujimura of the Japanese government admitted that nuclear substances were found in the waste of Japanese nuclear facilities. Although Japan did commit itself in 1977 to inspections in the safeguard agreement with the IAEA, the reports were kept secret for the inspectors of the International Atomic Energy Agency. Japan did start discussions with the IAEA about the large quantities of enriched uranium and plutonium that were discovered in nuclear waste cleared away by Japanese nuclear operators. At the press conference Fujimura said: "Based on investigations so far, most nuclear substances have been properly managed as waste, and from that perspective, there is no problem in safety management," but according to him, the matter was at that moment still being investigated.

=== 2026 Iran war === Following the assassination of Ali Khamenei during the 2026 Iran war, Badr Organization leader Hadi al-Amiri pledged allegiance to the new supreme leader of Iran, Mojtaba Khamenei.

=== Democratic Parliaments === 22nd South African Parliament (1994–1999) – majority party: African National Congress 23rd South African Parliament (1999–2004) – majority party: African National Congress 24th South African Parliament (2004–2009) – majority party: African National Congress 25th South African Parliament (2009–2014) – majority party: African National Congress 26th South African Parliament (2014–2019) - majority party: African National Congress 27th South African Parliament (2019–2024) - majority party: African National Congress 28th South African Parliament (2024–present) - no majority; plurality: African National Congress

Sources: en.wikipedia.org

Frequently asked questions

Is AOD-9604 approved for medical use?

No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.

Why is it banned in sports?

The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.

How is AOD-9604 detected?

Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.

How should AOD-9604 be stored?

Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.

Network